27598472|t|Endothermal venous ablation of the saphenous vein on patients who are on anticoagulation therapy
27598472|a|The purpose of this study was to evaluate the risks of bleeding, deep venous thrombosis (DVT), endovenous heat induced thrombosis (EHIT) and failure of ablation on patients who undergo ablation while on oral anticoagulation. We compared 378 (3.4%) out of 11252 patients (group A) who had undergone 724 endovenous ablation of the saphenous veins from January 1, 2011 to September 30, 2014 while on oral anticoagulation to a randomly selected 375 patients (group B) who underwent 641 endovenous ablation in the same time period but were not on anticoagulation. The demographic data, history of DVT, the Clinical, Etiologic, Anatomic, Pathologic (CEAP) classification and the VCSS (Venous Clinical Severity Score) scores were analyzed. The indications for anticoagulation, the anticoagulants used were recorded. The primary endpoints were bleeding, development of DVT or EHIT, and failure of ablation. Patients in group A were older, had more men, more history of DVT and PE, had higher CEAP and VCSS scores compared to group B. The type of anticoagulation used was warfarin in 77.2% direct oral inhibitors (DOIs) in 22.8%. The rate of failure of ablation at 3 days was 39 (5.6%) for Group A and 3 (0.5%) for Group B (P<0.0001) and at one month it was 46 (10.1%) vs. 27 (6.7%) (P=0.086). The number of EHIT cases in group A at 3 days was 2 (0.3%), compared to 6 (0.9%) in group B (P=0.016) and at 1 month it was 0 compared to 4 (1.0%) (P=0.0483). The DVT, SVT, hematoma and wound infection rates were similar in the two groups. Ablation of the saphenous veins in patients who are on oral anticoagulation is safe and does not increase the risk of bleeding or hematoma, but it may slightly lower the incidence of EHIT and increase the incidence of failure of ablation.
27598472	0	27	Endothermal venous ablation	T061	C2242647
27598472	35	49	saphenous vein	T023	C0036186
27598472	53	61	patients	T101	C0030705
27598472	73	96	anticoagulation therapy	T061	C0003281
27598472	117	122	study	T062	C2603343
27598472	143	148	risks	T078	C0035647
27598472	152	160	bleeding	T046	C0019080
27598472	162	184	deep venous thrombosis	T047	C0149871
27598472	186	189	DVT	T047	C0149871
27598472	192	226	endovenous heat induced thrombosis	T046	C0042487
27598472	228	232	EHIT	T046	C0042487
27598472	238	245	failure	T169	C0231174
27598472	249	257	ablation	T061	C0547070
27598472	261	269	patients	T101	C0030705
27598472	282	290	ablation	T061	C0547070
27598472	300	320	oral anticoagulation	T061	C0003281
27598472	325	333	compared	T052	C1707455
27598472	358	366	patients	T101	C0030705
27598472	368	375	group A	T185	C0441835
27598472	399	418	endovenous ablation	T061	C2242647
27598472	426	441	saphenous veins	T023	C0036186
27598472	494	514	oral anticoagulation	T061	C0003281
27598472	542	550	patients	T101	C0030705
27598472	552	559	group B	T185	C0441836
27598472	579	598	endovenous ablation	T061	C2242647
27598472	611	622	time period	T079	C1948053
27598472	639	654	anticoagulation	T061	C0003281
27598472	660	676	demographic data	T081	C0392762
27598472	678	688	history of	T033	C0332119
27598472	689	692	DVT	T047	C0149871
27598472	698	706	Clinical	T080	C0205210
27598472	708	717	Etiologic	T080	C0205556
27598472	719	727	Anatomic	T080	C0220784
27598472	729	739	Pathologic	T169	C1521733
27598472	741	745	CEAP	T080	C0205556
27598472	747	761	classification	T185	C0008902
27598472	770	774	VCSS	T081	C0392762
27598472	776	806	Venous Clinical Severity Score	T081	C0392762
27598472	834	845	indications	T078	C3146298
27598472	850	865	anticoagulation	T061	C0003281
27598472	871	885	anticoagulants	T121	C0003280
27598472	933	941	bleeding	T046	C0019080
27598472	958	961	DVT	T047	C0149871
27598472	965	969	EHIT	T046	C0042487
27598472	975	982	failure	T169	C0231174
27598472	986	994	ablation	T061	C0547070
27598472	996	1004	Patients	T101	C0030705
27598472	1008	1015	group A	T185	C0441835
27598472	1021	1026	older	T098	C3826770
27598472	1037	1040	men	T098	C0025266
27598472	1058	1061	DVT	T047	C0149871
27598472	1066	1068	PE	T047	C0034065
27598472	1081	1085	CEAP	T080	C0205556
27598472	1090	1094	VCSS	T081	C0392762
27598472	1114	1121	group B	T185	C0441836
27598472	1135	1150	anticoagulation	T061	C0003281
27598472	1160	1168	warfarin	T109,T121,T131	C0043031
27598472	1178	1200	direct oral inhibitors	T121	C1254351
27598472	1202	1206	DOIs	T121	C1254351
27598472	1222	1226	rate	T081	C1521828
27598472	1230	1237	failure	T169	C0231174
27598472	1241	1249	ablation	T061	C0547070
27598472	1255	1259	days	T079	C0439228
27598472	1278	1285	Group A	T185	C0441835
27598472	1303	1310	Group B	T185	C0441836
27598472	1329	1338	one month	T079	C4082115
27598472	1396	1400	EHIT	T046	C0042487
27598472	1401	1406	cases	T169	C0868928
27598472	1410	1417	group A	T185	C0441835
27598472	1423	1427	days	T079	C0439228
27598472	1466	1473	group B	T185	C0441836
27598472	1491	1498	1 month	T079	C4082115
27598472	1545	1548	DVT	T047	C0149871
27598472	1550	1553	SVT	T047	C0039240
27598472	1555	1563	hematoma	T046	C0018944
27598472	1568	1583	wound infection	T046	C0043241
27598472	1584	1589	rates	T081	C1521828
27598472	1614	1620	groups	T078	C0441833
27598472	1622	1630	Ablation	T061	C0547070
27598472	1638	1653	saphenous veins	T023	C0036186
27598472	1657	1665	patients	T101	C0030705
27598472	1677	1697	oral anticoagulation	T061	C0003281
27598472	1732	1736	risk	T078	C0035647
27598472	1740	1748	bleeding	T046	C0019080
27598472	1752	1760	hematoma	T046	C0018944
27598472	1792	1801	incidence	T081	C0021149
27598472	1805	1809	EHIT	T046	C0042487
27598472	1827	1836	incidence	T081	C0021149
27598472	1840	1847	failure	T169	C0231174
27598472	1851	1859	ablation	T061	C0547070